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Expression of glucose-6-phosphate dehydrogenase
(G6PD) gene during starvation and refeeding is regulated by a posttranscriptional mechanism occurring in
the nucleus. The amount of G6PD mRNA at different
stages of processing was measured in RNA isolated from
the nuclear matrix fraction of mouse liver. This nuclear
fraction contains nascent transcripts and RNA undergoing processing. Using a ribonuclease protection assay
with probes that cross an exon-intron boundary in the
G6PD transcript, the abundance of mRNAs that contain
the intron (unspliced) and without the intron (spliced)
was measured. Refeeding resulted in 6- and 8-fold increases in abundance of G6PD unspliced and spliced
RNA, respectively, in the nuclear matrix fraction. However, the amount of G6PD unspliced RNA was at most
15% of the amount of spliced RNA. During refeeding,
G6PD spliced RNA accumulated at a rate significantly
greater than unspliced RNA. Further, the amount of
partially spliced RNA exceeded the amount of unspliced
RNA indicating that the enhanced accumulation occurs
early in processing. Starvation and refeeding did not
regulate either the rate of polyadenylation or the length
of the poly(A) tail. Thus, the G6PD gene is regulated
during refeeding by enhanced efficiency of splicing of
its RNA, and this processing protects the mRNA from
decay, a novel mechanism for nutritional regulation of
gene expression.
Glucose-6-phosphate dehydrogenase (G6PD,1 EC 1.1.1.49) is
the rate-limiting enzyme of the pentose phosphate pathway.
All cells contain G6PD activity; however, nutritional and hormonal factors only regulate the expression of the enzyme in
liver and adipose tissue (1–3). Regulation of G6PD activity in
these tissues is because it plays a critical role in the de novo
synthesis of fatty acids by providing 50 –75% of the NADPH for
the fatty acid synthase reaction (4). Thus, G6PD is a member of
the lipogenic enzyme family. The activities of the lipogenic
enzymes are coordinately regulated so that flux of substrate
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through the fatty acid biosynthetic pathway is high when animals consume a diet rich in carbohydrate and flux is decreased
by starvation or the addition of polyunsaturated fat to the diet
(reviewed in Ref. 5). However, the molecular mechanisms causing these changes in flux vary considerably between enzymes.
The enzymes of the fatty acid biosynthetic pathway are regulated at both transcriptional and posttranscriptional steps.
Fatty acid synthase (6 – 8), acetyl-CoA carboxylase (9, 10), stearoyl-CoA desaturase (11), and ATP-citrate lyase (12) undergo
large changes in their transcriptional rates in response to dietary manipulations. Regulation of malic enzyme expression
during a chow to fat-free diet transition occurs by changes in
mRNA stability in the cytoplasm (13). In addition, cytoplasmic
mRNA stability is also involved in the regulation of stearoylCoA desaturase expression by fatty acids in yeast (14) and in
adipocytes (15). Posttranscriptional regulation is the primary
mechanism involved in the nutritional regulation of G6PD
expression and the mechanism involved occurs entirely within
the nucleus.
G6PD expression undergoes large changes in expression in
the livers of starved and refed mice and rats (3, 16, 17). These
nutritionally induced changes in G6PD activity are pretranslational (17–21). Despite the 12–15-fold increase in G6PD
mRNA abundance in the refed mouse, the transcriptional activity of the gene is not changed (22). This increase in cytoplasmic G6PD mRNA due to refeeding is accompanied by an increase in the amount of G6PD precursor mRNA (pre-mRNA) in
the nucleus implicating steps early in the processing pathway
as a potentially regulated point (23). Further, the increases in
the cytoplasmic pool of G6PD mRNA are preceded by changes
in the amount of the nuclear pool indicating that nuclear transport of the mature mRNA is not regulated (23). Nutritional
regulation of gene expression primarily at a nuclear posttranscriptional level is a novel observation for a lipogenic gene.
G6PD is an excellent model to further study nuclear posttranscriptional regulation because of the absence of transcriptional
changes, which confound the interpretation of results.
The steps involved in processing of nascent transcripts into
mature mRNA appear to be organized in a dynamic manner
within the nucleus. Both the transcription of an RNA and its
processing are spatially linked within the nucleus, such that
only the mature mRNA leaves the site of transcription. The
insoluble portion of the nucleus, which is the material remaining after sequential extraction of cells with detergent, DNase I,
and salt (24 –26), contains the hyperphosphorylated form of the
large subunit of RNA polymerase II, transcription factors, a
subset of small nuclear ribonucleoprotein particles, serine/arginine-rich (SR) protein splicing factors, and pre-mRNA (27–
34). The spatial link between transcription and processing appears to be facilitated by RNA polymerase II. Upon
phosphorylation of the C-terminal domain of polymerase II,
proteins involved in capping, splicing and polyadenylation bind

10514

This paper is available on line at http://www.jbc.org

Regulation of G6PD mRNA Processing by Nutritional Factors
to this domain and are thought to be transported to their site of
action during the elongation process (35, 36). RNA that is not
correctly processed does not leave the site of transcription and
is degraded (37). Thus, the entry of a nascent transcript into
the processing pathway and its efficient maturation are potential control points in the regulation of gene expression.
In this report, we present new results that nutritional regulation of G6PD expression occurs by changes in the efficiency of
G6PD pre-mRNA splicing. We have explored this mechanism
for regulation by measuring the amount of G6PD RNA that is
undergoing processing in the livers of mice during starvation
and refeeding a high carbohydrate diet. Refeeding a high carbohydrate diet enhanced the accumulation of G6PD mRNA in
the processing pathway. The enhanced accumulation of G6PD
mRNA was observed for RNA that was undergoing splicing
regardless of the presence or absence of the poly(A) tail. Further, the length of the poly(A) tail was not regulated by nutritional changes. Thus, regulation by changes in the efficiency of
pre-mRNA splicing represents an important mechanism for
control of gene expression by nutritional status. Understanding
the mechanisms by which nutrients alter nuclear posttranscriptional events will provide new information on the breadth
of mechanisms involved in gene regulation.
MATERIALS AND METHODS

Cell Culture—HepG2 cells (American Type Culture Collection, Rockville, MD) were grown in minimum essential medium (Life Technologies, Inc.) containing 110 mg/liter sodium pyruvate, penicillin (100
units/ml), streptomycin (100 g/ml) (Life Technologies, Inc.), and 10%
heat-inactivated fetal bovine serum (v/v; Life Technologies, Inc.) in a
humidified atmosphere at 37 °C and 5% CO2. MCF7 breast adenocarcinoma cells were a gift of Dr. Mike Miller (West Virginia University,
Morgantown, WV) and were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and gentamicin (50
g/ml). Rat hepatocytes were prepared as described previously (38).
Lysates of MCF7 cells and rat hepatocytes were prepared by sonication
of cells in phosphate-buffered saline (PBS).
Animal Care—Male C57BL/6 mice (NCI, Charles River Laboratory,
Frederick, MD; 4 weeks of age) were adapted to a reverse-cycle room
(light cycle 8 p.m. to 8 a.m.; dark cycle 8 a.m. to 8 p.m.) for 7 days while
maintained on a standard chow diet (Harlan Teklad). Adaptation to a
reverse light cycle permits the experiments to be done during typical
work hours. Mice were switched to a fat-free diet with glucose as the
carbohydrate source (PMI Feeds) supplemented with 1% (by weight)
safflower oil as a source of essential fatty acids. Diet was prepared fresh
daily, and the safflower oil was stored under N2 to minimize oxidation.
Mice received the high carbohydrate, low fat diet ad libitum for 7 days.
On day 8, the food was removed for a 24-h starvation period followed by
returning the diet for 24 h or for the times indicated in the figures.
Cellular Fractionation—Cellular fractionation was by a modification
of the method of Leppard and Shenk (39). All steps except the DNase I
digestion were preformed at ⫺20 °C with 40% glycerol added to the
buffers to prevent freezing (28). All solutions and glassware were
treated to be RNase-free. Intactness of the RNA was monitored using
Northern gels (data not shown); only intact RNA was used in subsequent steps. This modification was found to be superior to the use of
vanadyl ribonucleoside complexes or a placental ribonuclease inhibitor
in obtaining intact RNA.
Each mouse liver (or 2 ⫻ 107 cells in half the buffer volume) was
homogenized in 6 ml isotonic buffer (150 mM NaCl, 10 mM Tris䡠Cl, pH
7.5, 1.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, and 40% glycerol) with a motor driven Teflon pestle for 30 s. The cells were lysed by
addition of 300 l of 10% Nonidet P-40 (0.05%) and incubation at
⫺20 °C for 5 min. The cytoplasmic fraction was collected following
centrifugation at 2500 ⫻ g for 10 min. The crude nuclear pellet was
washed in 3 ml of isotonic buffer and then was resuspended in 3 ml of
isotonic buffer containing Nonidet P-40 (0.5%) and sodium deoxycholate
(0.25%). The mixture was vortexed and incubated at ⫺20 °C for 5 min.
The nuclear mixture was centrifuged as before, the supernatant was
reserved, and was the nuclear membrane fraction. The remaining nuclear pellet was washed in 2 ml of reticulocyte suspension buffer (RSB;
10 mM NaCl, 10 mM Tris䡠Cl, pH 7.5, 4 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, and 40% glycerol), pelleted as before, and the supernatant was added to the nuclear membrane fraction. The nuclear pellet
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was then resuspended in 500 l of RSB (no glycerol) and incubated with
RNase-free DNase I (1000 units, Life Technologies, Inc.) in the presence
of 500 units of Prime RNase inhibitor (5Prime 3 3Prime, Inc.) at 4 °C
for 25 min (for Western analysis, ribonucleoside vanadyl complexes (5
mM; Sigma) were added instead of the protein based inhibitor). At the
end of the DNase I digestion, glycerol (40%) was added and the mixture
was centrifuged (2500 ⫻ g, ⫺20 °C, 15 min). The supernatant was
reserved and was the nuclear soluble fraction. Nuclei were depleted of
digested chromatin and associated proteins by addition of 2 ml of RSB
and NaCl (1 M) and incubation for 10 min at ⫺20 °C. The remaining
nuclear material was pelleted as before, and the supernatant was added
to the nuclear soluble fraction. The final pellet of insoluble nuclear
material was reserved and is referred to here as the nuclear matrix (39).
RNA Isolation—RNA was isolated from the cytoplasm, nuclear membrane, and nuclear soluble fractions by addition of an equal volume of
denaturing solution (8 M urea, 350 mM NaCl, 10 mM Tris䡠Cl, pH 7.5, 10
mM EDTA, 1% SDS) (39). An equal volume of phenol/chloroform (6:4)
and 0.1 volume sodium acetate (2 M, pH 4.0) were added, and the
mixture was vortexed and incubated on ice for 15 min. Following
centrifugation to separate the layers, the aqueous phase from each
fraction was removed and the RNA was precipitated by addition of
equal volume of isopropanol. RNA from the nuclear matrix pellet was
isolated by the method of Chomczynski and Sacchi (40).
Nuclear RNA Isolation—Nuclei were prepared by the citric acid
protocol as described (23). RNA was isolated from the nuclear pellet by
the method of Chomczynski and Sacchi (40).
Electrophoresis and Western Blot Analysis—Proteins in the cellular
fractions (except nuclear matrix) were concentrated using a Centricon
30 (Amicon, Inc.). The protein concentration was measured by a modified Lowry method using bovine serum albumin as the standard (Sigma). The protein samples were separated by size in a 7.5% SDSpolyacrylamide gels in duplicate (41). One gel was stained with
Coomassie Brilliant Blue R-250, and the other gel was transferred to
polyvinylidene difluoride membrane at 500 mA overnight at 4 °C. Western analysis for NuMA (nuclear mitotic apparatus protein) used antiNuMA monoclonal antibody-1 (mAb-1; recognizes amino acids 900 –
2100, Oncogene Research Products; 1:500 dilution in PBS), and antiNuMA mAb-2 (recognizes amino acids 658 – 691, Oncogene Research
Products; 1:100 dilution in PBS) per the manufacturer’s instructions.
After washing with PBS, the blot was incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG (KPL) secondary antibody
(1:15,000 dilution in PBS). For detection of SRm160 (SR-related matrix
protein of approximately 160 kDa), mAb-B1C8 was used (42); mAbB1C8 was a gift of Dr. Jeffrey Nickerson (University of Massachusetts,
Worchester, MA). After washing with PBS, the blot was incubated with
horseradish peroxidase-conjugated goat anti-mouse IgM (KPL) secondary antibody (1:15,000 dilution in PBS plus Tween 20). In other experiments to detect the nonspecific binding, the primary antibody was
omitted. Signals were detected using the enhanced chemiluminescence
(ECL娂) detection kit according to the manufacturer’s instructions (Amersham Pharmacia Biotech).
Probes Designed for the Ribonuclease Protection Assay—Several
probes were designed for use in ribonuclease protection assays (Fig. 1).
In all cases, the full-length transcripts were designed to be larger than
the protected fragments so that incompletely digested probe could be
differentiated from the target signal in the ribonuclease protection
assay. All probes were sequenced to verify their structure. The nucleotide distribution in all probes and resulting protected fragments was
similar. Two G6PD probes, exon 2-intron 2 and intron 8-exon 9, were
made by polymerase chain reaction (PCR) amplification of a genomic
clone of G6PD using gene-specific primers and have been described
previously (23). The G6PD exon 2-intron 2 probe was shortened by 121
nt by digestion with KpnI. The next probe, which spans exon 8, intron
8, exon 9, and intron 9, was made to detect more than one pre-mRNA.
The pBG 2 subclone was made using a G6PD genomic clone (G6PD-B;
Ref. 22), which contains a 1.2-kilobase pair HindIII-SacI fragment
spanning intron 7-intron 9. This genomic subclone was digested with
HindIII, PstI, and SacI and the fragment spanning exon 8 to intron 9
was ligated into pBluescript KS⫹. Prior to use in the probe synthesis
reaction, the plasmid was linearized with XhoI. The final G6PD probe
spans the polyadenylation/cleavage site in the 3⬘-UTR so it can detect
the abundance of polyadenylated RNA after cleavage, as well as uncleaved RNA in a ribonuclease protection assay. DNA was amplified
using PCR between the XbaI site in the 3⬘-UTR of the G6PD mRNA and
157 nt downstream of the cleavage site. A Bpu1102I site was added to
the 3⬘ primer for cloning purposes. The amplified sequence was ligated
into pBluescript KS⫹, and the plasmid was linearized with NotI prior to
use in the probe synthesis reaction.
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The spot 14 subclone was synthesized from mouse genomic DNA by
PCR amplification. The 5⬘ primer was 5⬘-GGAATTCGCAGCCTCCATCACATCCTTAC-3⬘; the underlined sequence is an EcoRI site for subcloning followed by spot 14 exon 1 sequence (43). The 3⬘ primer was
5⬘-GGGATCCACCGCCATTTATCTCCTCCCTC-3⬘; the BamHI restriction site for subcloning is underlined and is followed by spot 14 intron
sequence (this sequence was kindly provided by Dr. Richard Planells,
INSERM, Marseille, France). The ␤-actin subclone was synthesized
from mouse genomic DNA by PCR amplification using the 5⬘ primer,
5⬘-GGAATTCGGCAGCGGCTGCTCTTGG-3⬘ and the 3⬘ primer, 5⬘-GGGATCCGCCCACGATGGAGGGGA-3⬘. The 5⬘ primer includes an EcoRI
restriction site (underlined) followed by ␤-actin intron 1 sequence (this
sequence was kindly provided by Dr. Michael Getz, Mayo Clinic, Rochester, MN). The 3⬘ primer includes the BamHI restriction site (underlined) followed by ␤-actin exon 2 sequence (44). Following amplification,

FIG. 1. Probes and protected fragments for the ribonuclease
protection assay. The lines and boxes schematically depict the structure of the precursor RNA. In each group of bars, the larger bar represents the size of the protected fragment in a ribonuclease protection
assay when the intron(s) is(are) present and the smaller bars are the
size of the protected fragments when the intron(s) has(ve) been spliced.
A probe for 18 S rRNA was used to demonstrate uniformity of RNA
loading. This probe protected an 80-bp fragment.
FIG. 2. SDS-PAGE and Western blot
analysis of cellular fractions. A, Coomassie Blue-stained PAGE-separated
proteins. Protein (20 g) from HepG2 cell
fractions (except the nuclear soluble fraction, 40 g) and from the cell lysates were
separated by size on 7.5% SDS-PAGE gel
and stained with Coomassie Blue. The
molecular mass markers are shown in the
last lane. The asterisk indicates a band,
which migrates at the size of NuMA.
Western blot analysis of cellular fractions
using anti-NuMA mAb-1 (B) and antiNuMA mAb-2 (C). Protein (20 g) from
HepG2 cell fractions (except nuclear soluble fraction, 40 g), along with 20 g of
protein from HepG2, MCF7, and rat hepatocyte cell lysate were separated by size
on a 7.5% polyacrylamide gel before
transfer to polyvinylidene difluoride
membrane, antibody staining, and detection as described under “Materials and
Methods.” The arrow indicates the position of NuMA. The numbers on the right
are the sizes of the molecular mass markers in kDa. D, Western blot analysis of
cellular fractions using mAb-B1C8. Protein (20 g) from HepG2 cell fractions,
HepG2 cell lysate, MCF7 nuclear matrix,
and rat hepatocyte lysate were separated
by size, transferred and stained as described under “Materials and Methods.”
The size of the antigen SRm160 is shown
on the left side of the blot.

the DNA fragments were gel-purified and ligated into pBluescript KS⫹.
The ␤-actin exon protected fragment (114 bp) was too close in size to the
spot 14 exon protected fragment (118 bp). Thus, the ␤-actin clone was
cleaved with SmaI and EcoRI and ligated into pBluescript KS⫹ restriction sites, resulting in a ␤-actin exon protected fragment of 90 bp.
The 18 S rRNA probe, which was used as a control for RNA loading,
was made from pRTI 18 S template (Ambion, Austin, TX). An additional
probe was made for chloramphenicol acetyltransferase (CAT) RNA, to
check for contamination of cytoplasm RNA into the nuclear fractions.
The CAT probe was derived from pRTI CAT (Ambion). To make both
sense and antisense CAT RNA, the pRTI CAT template was digested
with SstI and BamHI, blunt-ended, and ligated into the SmaI site.
Ribonuclease Protection Assay—Synthesis of the RNA probes using
an in vitro transcription reaction and the ribonuclease protection assay
were as previously described (23). RNA (20 g) was hybridized with 2 ⫻
104 cpm 32P-labeled each G6PD probe (specific activity ⬃108 cpm/g)
and 5000 cpm of 18 S rRNA probe (specific activity ⬃10,000 cpm/g) or
7 g of RNA hybridized with 4 ⫻ 104 cpm each of 32P-labeled spot 14
and ␤-actin probe (specific activity ⬃108 cpm/g) at 45 °C for 16 h. The
amount of probe was determined empirically to ensure that it was
present in molar excess over the transcript. The hybrids protected from
digestion with RNase were resolved in a 5% denaturing polyacrylamide
gel. The dried gel was placed into a storage phosphor cassette (for 1–3
days). Images were visualized and quantified using ImageQuaNT software (Molecular Dynamics). Statistical analysis in Fig. 5 was done
using analysis of variance, and the slopes were tested for parallelism.
RNase H Blot—RNase H analysis was done by a modification of the
method of Curthoys and Porter (45). Briefly, 30 g of RNA from the
nuclei of starved mice and 15 g of nuclear RNA from refed mice was
mixed with 370 ng of a G6PD specific oligonucleotide (5⬘-CTAAGGCTCCTCCCCATTGTTCC-3⬘, nucleotides 1972–1994 of the cDNA sequence)
(46). The mixture was heated to 70 °C and then cooled to room temperature over 10 min (47). Digestion with RNase H was for 20 min at 37 °C.
The samples were run on a Northern gel, transferred to GeneScreen,
and hybridized with a probe to the 3⬘ end of the G6PD mRNA.
Cross-contamination Experiment—Experiments were performed to
determine the amount of cytoplasmic RNA present in each nuclear
fraction. The 6 ml of homogenization buffer for each liver sample was
spiked with 5 ng of in vitro synthesized sense CAT RNA. Fractionation
was carried out as before. RNA (20 g) from each fraction was hybridized with 4 ⫻ 104 cpm 32P-labeled CAT antisense RNA and 5000 cpm 18
S rRNA in a ribonuclease protection assay. The cytoplasmic fraction
contained greater than 90% of total cellular RNA, while each nuclear
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fraction contained ⬃2% of the total cellular RNA. After correction for
these differences in RNA abundance between cellular fractions, 97% of
CAT RNA was retained in the cytoplasm, less than 1% of the CAT RNA
was in the nuclear membrane and nuclear soluble fractions, and less
than 0.01% was in the nuclear matrix fraction. These data indicate that
the cytoplasmic RNA contribution to the signal for spliced RNA in the
nuclear fractions was quite low.
RESULTS

Isolation of the Insoluble Nuclear Fraction—Regulation of
G6PD expression occurs at a step after transcription but prior
to the exit of the mRNA from the nucleus (23). Thus, the
potential regulatory step is during RNA processing. To measure G6PD RNA accumulation during processing, we used sequential extraction of cells with detergent, DNase I, and salt to
isolate the insoluble nuclear fraction. Isolation of this fraction
provides an experimental tool to measure pre-mRNAs that are
both newly synthesized and undergoing processing (28, 33, 48).
Further, RNA in the processing pathway is separated from
mature RNA at the nuclear pore. Historically, this fraction was
called the nuclear matrix, and we will use this term for simplicity. To validate our protocol, we used Western analysis with
antibodies against two proteins, NuMA and SRm160, which
are associated with the nuclear matrix (42, 49). Staining should
only occur against proteins of the expected size within the
nuclear matrix fraction. Appearance of these proteins in the
nuclear soluble and/or the nuclear membrane factions would
indicate that the detergent was extracting the nuclear matrix.
NuMA, also known as centrophilin (50), SPN (49), and SP-H
(51), is an ⬃240-kDa nuclear protein that resides at the spindle
poles during mitosis and is required for processing of precursor
mRNA during interphase (52, 53). Monoclonal antibodies
raised against NuMA (mAb-1 and mAb-2) only react with human NuMA antigen, thus, HepG2 cells were used as a source of
the cellular fractions. A different pattern of protein distribution
was observed in each cellular fraction upon staining the gel
with Coomassie Blue (Fig. 2A). An abundant nuclear protein
(asterisk in Fig. 2A) represents NuMA as confirmed by Western
analysis. Staining of the proteins in the cellular fractions with
NuMA mAb-1 detected its antigen (⬃240 kDa) predominantly
in the nuclear matrix fraction (Fig. 2B). The identity of this
protein as NuMA was confirmed with a second antibody to a
different epitope on the protein (Fig. 2C). Two additional bands
(approximately194 and 195 kDa) were detected in this fraction
corresponding to two additional isoforms of NuMA (54, 55). A
minor amount of NuMA was detected within the nuclear soluble fraction, but only when twice as much protein was loaded
onto the gel from this fraction as compared with the other
cellular fractions (Fig. 2B). The amounts of protein loaded on
the gel represent nearly all of the nuclear soluble fraction and
half of the nuclear matrix fraction. As expected, NuMA was
detected in HepG2 and MCF7 cell lysates, but not in rat hepatocytes, which was included as a negative control. Smaller
bands at ⬃160 and 180 kDa represent nonspecific binding
(data not shown; Refs. 52, 53, and 56).
A second nuclear matrix protein was detected using the
monoclonal antibody, B1C8, which recognizes SRm160, an SR
protein required for mRNA splicing (57, 58). Western blot analysis using B1C8, detected a 160 –180 kDa specific protein (42),
only in the HepG2 and MCF7 nuclear matrix fractions, but was
not detected in the cytoplasm, nuclear membrane, and nuclear
soluble fractions (Fig. 2D). The band detected at ⬃160 kDa in
the rat hepatocyte lysate appeared to be nonspecific and was
also observed during staining with anti-NuMA antibodies (Fig.
2, A and B). Thus, the retention of SRm160 and NuMA within
the nuclear matrix fraction indicated that this subcellular
structure was not extracted to any great extent into other
fractions during the isolation protocol.

FIG. 3. Effects of starvation and refeeding on G6PD mRNA
abundance in each cellular fraction. Mice were provided access to
the high carbohydrate, low fat diet ad libitum for 1 week. After 24 h of
starvation, 6 mice were sacrificed (starved) and the high carbohydrate,
low fat diet was returned to the other 6 mice for 24 h (refed). The livers
from 3 mice from each group were fractionated and the other 3 livers
were used to isolate nuclear RNA. RNA (20 g) from cellular fractions
(or 20 g of nuclear RNA) was hybridized with each of the G6PD probes
(exon 2-intron 2 and intron 8-exon 9) and the 18 S rRNA probe in a
ribonuclease protection assay as described under “Materials and Methods.” Each lane represents a cellular fraction from a single mouse. The
size of G6PD exon 2-intron 2, G6PD intron 8-exon 9, and 18 S rRNA
full-length probes are 334, 320, and 162 nt, respectively. The positions
of the protected fractions for G6PD exon 2-intron 2 (Ex2-In2), exon 2
(Ex2), and G6PD intron 8-exon 9 (In8-Ex9), exon 9 (Ex9), and 18 S rRNA
are shown. D, digested control (hybridization of 30 g of yeast RNA with
both probes followed by RNase digestion). UN, undigested control (hybridization of 30 g of yeast RNA with both probes without RNase
digestion). Only 5% of the undigested control reaction was loaded onto
the gel. M, RNA marker in nucleotides. These data are representative
of three independent experiments that showed similar results.

Effects of Starvation and Refeeding on G6PD mRNA Abundance in Each Cellular Fraction—Starvation and refeeding
produce the greatest changes in the amount of G6PD mRNA in
both the cytoplasm and the nucleus (23). Thus, we used this
dietary paradigm to determine changes in the amounts of
G6PD pre-mRNA during processing. We used two probes, separated by 12 kilobase pairs, to detect G6PD RNA. Each probe
hybridized across an exon-intron junction and resulted in two
protected fragments (Figs. 1 and 3). The longer fragment (exon
2-intron 2; intron 8-exon 9) corresponds to unspliced RNA that
contains both the exon and intron sequences; the smaller fragment (exon 2; exon 9) corresponds to spliced RNA that only
contains the exon sequences. The terms unspliced and spliced
must be used cautiously because each probe provides information about the splicing of only 1 of the 12 introns in the G6PD
gene.
In these and later experiments, a probe for 18 S rRNA was
included in the reactions to control for RNA loading in the
RNase protection assay. 18 S rRNA was present in all the
cellular fractions (Fig. 3). The variation in 18 S rRNA amounts
between lanes was less than 15% in this (Fig. 3) and later
figures. Significant amounts of 18 S rRNA were observed
within the insoluble fraction of the nucleus. The large amounts
in the nuclear membrane and nuclear soluble fractions most
likely represent movement of 18 S rRNA through the nucleus
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FIG. 4. The -fold induction of G6PD mRNA abundance in each
cellular fraction due to refeeding. This figure shows the cumulative
results of three independent experiments carried out as described in the
legend to Fig. 3. The amounts of the two G6PD protected fragments
(exon 2 and exon 2-intron 2 (Ex2-In2)) were quantified in each of the
cellular fractions from the livers of starved and refed mice (mean ⫾
S.E., representing 10 mice). Each bar represents the value (in ImageQuaNT units) of each protected fragment in that fraction from refed
mice divided by the value of that protected fragment in the same
cellular fraction from starved mice.

as well as cytoplasmic contamination of these fractions.
In refed mouse liver, unspliced G6PD mRNAs were detected
in greatest abundance in the nuclear matrix fraction and to a
lesser extent in the nuclear soluble and nuclear membrane
fractions (Fig. 3). We detected a very small portion of G6PD
pre-mRNA in the cytoplasm. This is the result of rupture of the
nucleus during the fractionation due to the low temperature
(⫺20 °C) used; pre-mRNA in the cytoplasm was not observed
when the fractionation was performed at 4 °C (data not shown).
Curiously, nuclear matrix proteins were not detected in the
cytoplasm (Figs. 2, B–D). This may reflect that pre-mRNAs are
less tightly associated with the nuclear matrix fraction than
the protein components. Regardless, the majority of the
pre-mRNA was localized to the nucleus.
Consistent with our previous results (22, 23), the abundance
of G6PD mRNA in the cytoplasm was very low after 24 h of
starvation as measured with the exon 2 and exon 9 protected
fragments (Fig. 3). Refeeding the starved mice caused a 16 –20fold increase in the abundance of G6PD mRNA in the cytoplasm (Fig. 4). During starvation, the amount of G6PD mRNA
was uniformly low in all nuclear fractions regardless of the
extent of processing of the mRNA. Upon refeeding, the amount
of G6PD unspliced RNA (exon 2-intron 2 and intron 8-exon 9)
increased 6-fold in the nuclear matrix fraction (Fig. 4). The
amount of unspliced RNA on the nuclear matrix could account
for nearly all of this class of RNA in total nuclear RNA (Fig. 3).
An increase of 2-fold or less in G6PD unspliced RNA was also
observed in the nuclear soluble and nuclear membrane fractions, but the amount of unspliced RNA was close to detection
limits. Refeeding resulted in an 8-fold increase in the abundance of G6PD spliced RNA (exon 2 and exon 9) on the nuclear
matrix (Figs. 3 and 4). Although the -fold increase in spliced
versus unspliced G6PD mRNA abundance did not vary significantly, the absolute amounts of spliced versus unspliced RNA
were substantially different. In the refed mice, the amount of
spliced RNA was 11-fold greater than the amount of unspliced
RNA (2334 ⫾ 290 versus 212 ⫾ 40 phosphorimager units/nt for
spliced versus unspliced RNA; exon 2-intron 2 probe). An in-

FIG. 5. Kinetics of G6PD mRNA accumulation in the cytoplasm
(A) and the nuclear matrix (B) during 24 h refeeding. Mice (n ⫽
28) were provided access to the low fat diet ad libitum for 1 week. After
24 h of starvation, the low fat diet was returned for up to 24 h (refeeding
period). Four mice were sacrificed every 4 h up to 24 h, starting at time
point 0 (starved mice). The livers were removed from the mice, fractionated and RNA was isolated from each fraction (see “Materials and
Methods”). A, RNA from the cytoplasmic fraction (20 g) from each
mouse liver was hybridized with the two G6PD probes (exon 2-intron 2
and intron 8-exon 9) and the 18 S rRNA probe in a ribonuclease
protection assay. The amounts of G6PD spliced RNA, exon 2 (Ex2), and
exon 9 (Ex9) protected fragments were quantified using ImageQuaNT
software and the resulting values were adjusted for the size of the
protected fragment. Each point represents the mean ⫾ confidence interval (n ⫽ 4 mice/time point except the 24-h time point with n ⫽ 6 mice;
90% confidence). P.I. Un., phosphorimage units. B, RNA (20 g) from
the nuclear matrix fractions of each mouse liver was hybridized with
the G6PD and 18 S rRNA probes (as above) in a ribonuclease protection
assay. Amounts of G6PD spliced RNA (Ex2, and Ex9 protected fragments) and unspliced RNA, exon 2-intron 2 (Ex2-In2) and intron 8-exon
9 (In8-Ex9) protected fragments were quantified using ImageQuaNT
software; each value was divided by the size of the fragment. Each point
represents the mean ⫾ confidence interval (n ⫽ 4 mice/time point
except the 24-h time point with n ⫽ 6 mice; 90% confidence). In some
cases the confidence interval bars do not extend beyond the size of the
symbol.

creased amount of spliced RNA was also observed in the nuclear soluble and nuclear membrane fractions. Similar results
were observed with G6PD intron 8-exon 9 probe in all experiments (Fig. 3). Thus, starvation and refeeding resulted in
changes in the amount of G6PD pre-mRNAs in the processing
pathway, and the amount of spliced G6PD RNA was consistently greater than the amount of unspliced RNA.
Kinetics of G6PD mRNA Accumulation in Cytoplasm and
Nuclear Matrix during 24-h Refeeding—Changes in the
amount of G6PD spliced RNA in the nucleus could be caused by
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FIG. 6. Effects of starvation and refeeding on the spot 14 and
␤-actin mRNA abundance in the cellular fractions. RNA (7 g)
isolated from cellular fractions or nuclear RNA (from same mouse livers
as in Fig. 4) was hybridized with the spot 14 and ␤-actin probes in a
ribonuclease protection assay. Each lane represents a cellular fraction
from a single mouse. The size of spot 14 exon 1-intron 1 and ␤-actin
intron 1-exon 2 full-length probes are 246 and 218 nt, respectively. The
positions of the protected fragments for spot 14 exon 1-intron 1 (Ex-In)
and exon 1 (Ex), and for ␤-actin intron 1-exon 2 (In-Ex) and exon 2 (Ex)
are shown. D, digested control (hybridization of 7 g of yeast RNA with
both probes followed by RNase digestion). UN, undigested control (hybridization of 7 g of yeast RNA with both probes without RNase
digestion). Only 5% of the undigested control reaction was loaded onto
the gel; a lighter exposure of undigested was included for clarity. M,
RNA markers in nucleotides. These data are representative of three
independent experiments that showed similar results.

changes in either the rate of its production due to processing of
the nascent transcript or degradation of this pool of mRNA. To
further investigate the differences in the amount of G6PD
unspliced versus spliced RNA, we measured mRNA accumulation with time during refeeding. In mice that had been starved
for 24 h (0 time point), the amount of G6PD mRNA was very
low in both the cytoplasm and the nuclear matrix fractions
(Fig. 5, A and B). In the cytoplasm, accumulation of G6PD
mRNA occurred with two different rates. During the first 8 h,
G6PD mRNA increased 3-fold but at a slow rate (Fig. 5A). An
increase of 12–16-fold was observed 24 h after refeeding, and
the rate of accumulation was faster between 8 and 24 h. In the
nuclear matrix fraction, G6PD unspliced RNA was present in
very low abundance at all time points, consistent with the lack
of transcriptional regulation of this gene. The amount of unspliced RNA accumulated at a linear rate (r ⫽ 0.99) of ⬃22 and
7 units/h (exon 2-intron 2 and intron 8-exon 9, respectively)
over 16 h of refeeding (Fig. 5B). This small increase is due to
splicing at other intron/exon boundaries not measured by these
probes. A 3– 4-fold increase was observed in the rate of accumulation of G6PD spliced RNA compared with unspliced RNA
accumulation during the same period (86 and 63 units/h, for
exon 2 and exon 9, respectively). This rate was linear (r ⫽ 0.99)
over 16 h of refeeding but continued to increase through 24 h.
Furthermore, these increases in rate between the spliced and
unspliced pools of RNA were significant (p ⬍ 0.0001 for both
exon 2-intron 2 versus exon 2 and intron 8-exon 9 versus exon
9). At all time points, the amount of G6PD unspliced RNA was
markedly less than the amount of spliced RNA (Fig. 5B); however, both pools of RNA increased during refeeding. The more
rapid accumulation of spliced RNA suggests that refeeding

FIG. 7. Kinetics of spot 14 mRNA accumulation in the cytoplasm (A) and the nuclear matrix (B) during 24 h refeeding. A,
RNA (7 g) from the cytoplasmic fraction from each mouse liver (same
mice as in Fig. 6) was hybridized with the spot 14 probe in a ribonuclease protection assay. The amount of spot 14 spliced mRNA (Exon)
protected fragment was quantified using ImageQuaNT software. Each
point represents the mean ⫾ S.E. (n ⫽ 4 mice/time point except the 24-h
time point with n ⫽ 6 mice). B, RNA (7 g) from the nuclear matrix
fraction from each mouse liver (as above) was hybridized with the spot
14 probe in a ribonuclease protection assay. The amounts of spot 14
spliced mRNA (Ex) and precursor mRNA (Ex-In) protected fragments,
were quantified using ImageQuaNT software and corrected for the size
of the protected fragment. The values are normalized to ␤-actin to
correct for loading differences; ␤-actin expression did not vary during
this time course (data not shown). Each point represents the mean ⫾
S.E. (n ⫽ 4 mice/time point except the 24-h time point with n ⫽ 6 mice).
In some cases the S.E. bars do not extend beyond the size of the symbol.
P.I. Un., phosphorimage units.

enhances the rate of production of this RNA.
Effects of Starvation and Refeeding on Spot 14 and ␤-Actin
mRNA Abundance in Each Cellular Fraction—The nuclear
posttranscriptional regulation observed with the G6PD gene is
not a commonly described mechanism. To determine whether
related and unrelated genes share this mechanism, we measured the changes in the abundance of precursor and mature
mRNA for a gene that is transcriptionally regulated in response to starvation and refeeding and a gene that is unregulated by this dietary paradigm. The spot 14 gene undergoes
large changes in its transcription rate in response to dietary
and hormonal stimuli (59, 60). In addition, spot 14 mRNA
abundance is also regulated posttranscriptionally (61– 63).
Spot 14 contains only one intron, thus, the protected fragments
corresponding to unspliced (exon 1-intron 1) and spliced (exon
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1) represent the spot 14 precursor and mature mRNA, respectively (Fig. 1; Ref. 64). The amounts of both unspliced and
spliced spot 14 mRNA were very low in the livers starved mice.
Refeeding increased both the unspliced and spliced RNA in the
nucleus and the mature mRNA in the cytoplasm (Fig. 6). In
contrast to G6PD, the ratio of unspliced to spliced spot 14
mRNA was much greater. In this regard, the amount of unspliced RNA on the nuclear matrix was 63% or more of the
amount of spliced spot 14 mRNA in this fraction.
␤-Actin, a constitutively expressed gene, is not involved in
intermediary metabolism and is not regulated to any great
extent by these nutritional manipulations (22). We detected a
very small amount of ␤-actin unspliced RNA in the livers of
starved and refed mice, whereas the amount of spliced RNA
was clearly detectable in all cellular fractions (Fig. 6). The
amount of ␤-actin spliced RNA in each cellular fraction was
increased 2-fold after refeeding; however, marginal changes in
the amount of ␤-actin mature mRNA due to dietary manipulation were not unexpected (65). The physiological relevance of
this increase in actin expression is not clear. The increase in
expression was detectable by 4 h of refeeding and the amount
of actin mRNA (both unspliced and spliced) remained constant
over the 24 h of refeeding (data not shown). Changes in the
transcriptional activity of the actin gene are not seen throughout this time period (22). Despite the absence of large changes
in the expression of the ␤-actin gene due to nutritional status,
the ratio of unspliced to spliced RNA for this gene resembled
that of G6PD and not the transcriptionally regulated spot 14
gene.
Kinetics of Spot 14 mRNA Accumulation in Cytoplasm and
Nuclear Matrix during 24-h Refeeding—The amounts of unspliced versus spliced RNA on the nuclear matrix were clearly
different between spot 14, which is transcriptionally regulated
by dietary status, and G6PD, which is not regulated transcriptionally. We next examined the kinetics of spot 14 mRNA
accumulation in the cytoplasm and the nuclear matrix. Enhanced accumulation of spot 14 mature mRNA was detected in
the cytoplasm as early as 4 h after refeeding and increased
accumulation continued through 24 h (Fig. 7A). In the nuclear
matrix fraction, the abundance of spot 14 unspliced RNA increased dramatically with refeeding (Fig. 7B). This increase is
consistent with an increase in production of this mRNA due to
transcriptional regulation of the gene (60) and is in sharp
contrast to the changes in unspliced RNA abundance with
G6PD, which does not undergo transcriptional regulation.
However, at all time points, the amount of spliced RNA exceeded the amount of unspliced RNA. This increase in spliced
mRNA compared with unspliced is consistent with previous
reports (61). Thus, transcriptional regulation of spot 14 appears to be coupled with posttranscriptional changes in the
rate of mature mRNA formation. Enhanced processing of
mRNA may be a common mechanism for nutritional regulation
of gene expression.
Effects of Starvation and Refeeding on Accumulation of
G6PD Splicing Intermediates—We next sought to distinguish if
stabilization of the message is occurring during processing
itself or if it is the fully spliced form of the message that is
stabilized. A probe was designed that contained two introns
and thus detected pre-mRNA at three different stages in splicing: 1) both introns present, 2) removal of only one of the two
introns, and 3) removal of both introns. As illustrated in Fig. 8,
hybridization of G6PD pBG 2 probe, which spans two consecutive exon-intron boundaries (exon 8-intron 8-exon 9-intron 9),
with nuclear matrix mRNA resulted in detection of four protected fragments (Fig. 8). The exon 8-intron 8-exon 9-intron 9
(A) protected fragment represents mRNA in which both introns

FIG. 8. Effects of starvation and refeeding on accumulation of
G6PD splicing intermediates. RNA was isolated from starved or
refed mice as explained in the legend to Fig. 3. A, RNA (20 g) from
nuclear matrix fractions was hybridized with G6PD pBG 2 probe, which
spans the exon 8, intron 8, exon 9, and intron 9 in ribonuclease protection assay. The size of pBG 2 full-length probe (627 nt) is shown on the
right. The protected fragments include G6PD exon 8-intron 8-exon
9-intron 9 (E8 I8 E9 I9, 577 nt) (A), G6PD exon 8-exon 9-intron 9 (E8 E9
I9, 389 nt) (B), G6PD exon 9 (E9, 187 nt) (C), and G6PD exon 8 (E8, 67
nt) (D). At the top of the gel, D represents digested control (hybridization of 30 g of yeast RNA with both probes followed by RNase digestion) and UN represents undigested control (hybridization of 30 g of
yeast RNA with probe without RNase digestion). Only 5% of the undigested control reaction was loaded onto the gel. M, RNA marker as in
Fig. 6. Panel A is representative of a single starved and refed mouse;
data from three other starved and refed mouse showed similar results.
Panel B, each protected fragment from A was quantified using ImageQuaNT software as phosphorimage units (P.I. Un.). The phosphorimage
units were divided by the length of each protected fragment (nt). The
ratio of each splicing intermediate species (B, C, and D) to unspliced
pre-mRNA (A) is shown. These results are similar to three additional
experiments using total nuclear RNA (M. A. Gibson and L. M. Salati,
unpublished data).

are still present. The G6PD exon 8-exon 9-intron 9 (B), exon 9
(C), and exon 8 (D) protected fragment represents successive
removal of intron 8 and then intron 9 (Fig. 8). A protected
fragment representing removal of intron 9 but containing intron 8 (375 nt) was not detected, indicating that order of intron
removal was intron 8 followed by intron 9. Successive removal
of introns from the mRNA resulted in an increase in the
amount of spliced RNA for G6PD both in refed and starved
state. However, even RNA from which only one of the two
detectable introns had been spliced was increased in amount
relative to RNA that contained both introns. A greater increase
was observed in the amount of RNA from which two introns
had been spliced. A similar observation was made in four
additional experiments using nuclear RNA (data not shown).
Comparison of the amounts of partially spliced mRNA during
starvation and refeeding indicated that refeeding stimulated a
greater accumulation of this intermediately spliced mRNA
(B/A 2.8 versus 1.1). Continued splicing further stimulated
RNA accumulation (C/A 20.2 versus 4.8; D/A 28.9 versus 6.8).
Thus, the regulated increase in G6PD RNA accumulation in-
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FIG. 9. The effects of refeeding on the G6PD mRNA 3ⴕ end
processing. The animal handling and the RNA isolation were the
same as described in the legend to Fig. 5. A, nuclear matrix RNA
isolated from 3– 4 mice at each time point (0, 4, 8, 12, and 16 h of
refeeding) was pooled and used in ribonuclease protection assays. RNA
was hybridized with G6PD exon 2-intron 2 (Ex2-In2) and 3⬘-UTR
probes. B, the 3⬘-UTR probe hybridizes to a region 138 nt upstream and
150 nt downstream of the polyadenylation/cleavage site. RNA hybridization with the 3⬘-UTR probe resulted in two protected fragments,
pre-mRNA that are not yet cleaved (unpolyadenylated RNA), and the
cleaved RNA (therefore polyadenylated RNA). The abundance of each
protected fragment was quantified using ImageQuaNT software and
corrected for the length of the protected fragment.

volves events earlier in the RNA processing pathway and not
merely stabilization of the mature mRNA.
Effects of Refeeding on the 3⬘ End Processing of the G6PD
mRNA—Events early in processing that could regulate
pre-mRNA accumulation include splicing and 3⬘ end formation
(cleavage and polyadenylation). To distinguish between these
two possibilities, we measure the accumulation of uncleaved
versus polyadenylated RNA during refeeding. A probe to the
3⬘-UTR was hybridized with RNA samples from starved and
refed mice. The 3⬘-UTR probe resulted in the detection of two
protected fragments. A protected fragment of 288 nt corresponded to uncleaved pre-mRNA (therefore unpolyadenylated
RNA). The second protected fragment (138 nt), represented the
polyadenylated mRNA (Fig. 9). Cleaved mRNA that had not
been polyadenylated was not detected.2 The abundance of uncleaved pre-mRNA was very low both in starved mice and in
mice after 16 h of refeeding, suggesting that this species of
mRNA was being synthesized at a basal level and accumulating very slowly during refeeding (rate of 8 phosphorimage
units/h, r ⫽ 0.95). The G6PD intron 2-exon 2 probe was used
with the same aliquot of mRNA as a control to compare with
previous results. The abundance of polyadenylated mRNA in2

C. D. Shrader and L. M. Salati, unpublished data.
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FIG. 10. Nutritional status does not regulate the length of the
G6PD poly(A) tail. Nuclear RNA was isolated from mice that had been
starved for 24 (lanes 1 and 2) or from mice that had been starved and
then refed the high carbohydrate diet for 24 h (lanes 3, 4, and 5). RNA
was hybridized with a G6PD-specific oligonucleotide (lanes 1– 4) or
without the oligonucleotide (lane 5). Following RNase H digestion, the
products were separated by size on a Northern gel and probed with a
G6PD probe for sequences 3⬘ of the digestion site. The markers on the
right side of the figure indicate the positions of the full-length G6PD
mRNA and the 3⬘-fragments containing G6PD sequence and the poly(A)
tail. The numbers on the left of the figure indicate the size of the
molecular weight markers. This experiment was repeated four times
with the same results.

creased 8-fold similar to the G6PD unspliced mRNA (exon
2-intron 2 protected fragment) with refeeding. Likewise, the
rate of accumulation of the polyadenylated RNA was similar to
that for unspliced RNA during the first 12 h of refeeding (slope
of 78 (r ⫽ 0.95) versus 30 (r ⫽ 0.98) for polyadenylated and exon
2-intron 2, respectively). In contrast, the rate of accumulation
of spliced mRNA (exon 2 protected fragment) was 149 (r ⫽
0.97), nearly twice the rate of polyadenylated RNA accumulation. Consistent with previous results, the amount of unspliced
mRNA (exon 2-intron 2 protected fragment) was 25% of the
amount of spliced mRNA. Thus, accumulation of G6PD mRNA
requires polyadenylation but the rate of accumulation of this
pool of RNA is not sufficient to account for the enhanced rate of
mature RNA formation during refeeding.
To further verify that events involved in the formation of the
3⬘ end of G6PD mRNA, the length of the poly(A) tail was
measured. Shortening of the poly(A) tail can destabilize mRNA
(cf. Refs. 66 and 67). Nuclear RNA isolated from the livers of
mice that had been starved or starved and then refed was
subjected to RNase H analysis (Fig. 10). The size of the 3⬘
fragment resulting from RNase H digestion was slightly
greater than 500 nt. Of this sequence, 327 nt corresponds to the
G6PD 3⬘-UTR and the remaining 173 or more nucleotides represent the poly(A) tail. Starvation and refeeding did not alter
the length of the poly(A) tail. Taken together, these results
indicate that the rate of formation of the 3⬘ end of the G6PD
mRNA is not affected by dietary status. Thus, regulation of
G6PD by starvation and refeeding is due to changes in the
efficiency at which the pre-mRNA is spliced.
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DISCUSSION

Hepatic G6PD activity and mRNA abundance undergo large
changes with dietary manipulations both in vivo and in primary hepatocyte cultures (22, 38). In this study, we present our
results that the efficiency of RNA splicing is the step regulating
G6PD pre-mRNA accumulation during refeeding. Several lines
of evidence indicate that splicing is the step regulating G6PD
RNA accumulation. The following model summarizes this
regulation.

probe (Fig. 5). The simplest explanation is that this reflects
differences in specific activity of the probes and/or their hybridization efficiency. Alternatively, it may reflect an important
regulatory phenomenon. Discriminating between these alternatives will require precise mapping of the regulatory element(s) and is the subject of current investigations in the
laboratory.
The failure to accumulate G6PD pre-mRNA in the starved
mouse suggests that transcripts that fail to be fully processed

SCHEME I

The reactions are listed in this order for illustration purposes
only. Splicing and polyadenylation occur cotranscriptionally
(35, 68); thus, splicing (k2 and k4) and polyadenylation (k3) are
most likely occurring coincidentally.
In previous reports from our laboratory, we demonstrated
that the transcriptional activity (k1) of the G6PD gene is not
regulated by starvation or refeeding and in fact of the rate of
G6PD transcription is very low. However, refeeding results in
increases in the accumulation of both partially spliced and
mature forms of G6PD mRNA in the nucleus. Thus, regulation
of G6PD expression is occurring at a posttranscriptional step in
the nucleus. Nuclear posttranscriptional regulation can involve
changes in the rate of degradation of the RNA (i.e. k5– 8) or
regulation of the efficiency of steps in processing (i.e. k2– 4) of
the primary transcript. The rate of degradation of a mRNA can
be regulated by both the presence of a poly(A) tail and the
length of this tail. In this regard, the rate of accumulation of
nonpolyadenylated RNA (k2) was the slowest of all measured,
but did increase during refeeding (Fig. 9). The increase in the
rate of accumulation of polyadenylated RNA (k3) was insufficient to account for the overall rate of accumulation of mature
mRNA in the nucleus. We also examined the structure of the 3⬘
end of G6PD RNA and found no difference in the length of the
poly(A) tail between the starved and refed states (Fig. 10).
Thus, the rate of degradation (k7) would be unchanged by these
nutritional manipulations. These results indicate that polyadenylation of the RNA while necessary for accumulation of
G6PD RNA does not cause the high rates of accumulation of
G6PD mRNA during refeeding. It is during the splicing of
G6PD pre-mRNA that the greatest increases in rate were observed (k2 and k4), and it is the rate of accumulation of the fully
processed RNA (k4) that was most enhanced (Figs. 5, 8, and 9).
During starvation, splicing is not enhanced and the decrease in
the rates of k2 and k4 will result in enhanced degradation of the
G6PD transcripts in the nucleus (k6 and k7). Once fully processed, G6PD mRNA is stable in the nucleus and no change in
its rate of degradation (k8) is detectable across dietary manipulations (23).
The precise structure with respect to numbers of introns
remaining in the RNA that is stabilized is not known. The
G6PD gene is 18 kilobase pairs and contains 12 introns. Since
splicing is most likely occurring cotranscriptionally, most certainly the stabilized RNA is partially spliced. Curiously, the
amount of RNA detected with the more 5⬘ probe (exon 2-intron
2) was consistently greater than the amount measured with the
more 3⬘ probe (intron 8/exon 9) and the rate of accumulation of
the RNA was slightly greater when measured with the 5⬘-most

are degraded within the nucleus. In this regard, mutations
thateffect splicing or polyadenylation result in degradation of
the RNA in the nucleus (37, 69). Degradation of the partially
spliced G6PD transcript must be rapid and most likely takes
place while the nascent transcript is at the site of transcription
because we did not detect any increase in the abundance of
pre-mRNA in other nuclear fractions from the livers of starved
mice (Fig. 3). Even in the starved state, G6PD expression is
still required for cell viability (70). Thus, even at low levels of
G6PD expression, the increase in spliced RNA relative to unspliced RNA was detectable.
Only a few examples have been reported of nuclear posttranscriptional regulation. These include expression of fibronectin
(71), alkaline phosphatase (72, 73), interleukin-2 (74), tumor
necrosis factor-␣ (75), peptidylglycine ␣-amidating monooxygenase (76), and spot 14 (61). Regulation of fibronectin expression
by dexamethasone involves changes in pre-mRNA amounts
without changes in transcription rate of the gene (71). In the
case of the alkaline phosphatase gene, its pre-mRNA is only
processed to mature mRNA when the cells are treated with
retinoic acid (73). During T cell activation, mitogens stimulate
expression of the interleukin-2 gene by stimulated the accumulation of precursor transcripts for interleukin-2 in the nucleus,
in the absence of transcriptional changes (74). Similarly, tumor
necrosis factor-␣ mRNA is also induced during T cell activation
by changes in the efficiency of its splicing (75). A cis-acting
element in the 3⬘-UTR of the transcript enhances splicing of
this mRNA (75). An example of destabilization of pre-mRNA in
the nucleus is observed with peptidylglycine ␣-amidating monooxygenase mRNA accumulation in the anterior pituitary.
Analysis of the nuclear RNA showed that decreased peptidylglycine ␣-amidating monooxygenase expression after 17␤-estradiol treatment was primarily due to intranuclear destabilization of the primary transcript (76). Together, these data are
consistent with the presence of a nuclear pathway for RNA
degradation.
In contrast to examples that only involve posttranscriptional
regulation, nutritional regulation of spot 14 occurs by large
changes in the rate of transcription of this gene (60). However,
along with the large transcriptional changes, dietary carbohydrate, and insulin result in accumulation of splicing intermediates for spot 14 pre-mRNA and an increased ratio of mature
to pre-mRNA (61, 62). Thus, nuclear posttranscriptional regulation is not exclusive to genes that lack transcriptional regulation. We have confirmed these findings and found that, like
G6PD, the amount of spot 14 spliced RNA was increased during
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refeeding (Fig. 7). Regulation of this gene by both transcriptional and posttranscriptional mechanisms would result in a
more rapid response to changing nutritional conditions. Further, these results suggest that regulation of the efficiency of
splicing may be involved in the regulation of other lipogenic
enzymes; it simply has not been studied due to the large transcriptional regulation of these genes (5). It remains to be determined if the fine details of this nuclear posttranscriptional
regulation are the same across the genes known to exhibit this
form of regulation.
Splicing is known to be regulatory in a number of physiological situations. The mechanisms involved in nuclear degradation remain to be determined. Two pathways have been identified that could regulate nuclear pre-mRNA levels. One
pathway has been observed when splicing of a transgene was
blocked by mutation, e.g. inhibition of splicing of a ␤-globin
transgene resulted in the failure to further process the mRNA
and it was degraded within the nucleus (37). Nuclear degradation can also involve the presence of a premature termination
codon in the mRNA (77, 78). Apart from genetic mutations, a
premature termination codon could arise due to the prolonged
presence of an intron in the pre-mRNA. Distinguishing between these possibilities in the regulation of G6PD expression
is the subject of future experiments in the laboratory.
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